About us Newsletter News Widget Media Inquiries

Media Inquiries

Your experience will be better in the app

Install

Sign Up | Log In

Menu

Contact Us Terms of Service Support Privacy Policy Archive

© 2024 Otherweb

Follow

Featured Podcast EpisodesThe Other Web

Alex Fink

Zuckerman vs Zuckerberg

July 14, 2024

Ethan Zuckerman is a professor at the University of Massachusetts Amherst and a scholar of digital media. He and his team work to understand the contemporary digital world and build social media systems that are focused on communities, not on profits. Ethan is currently suing Meta (i.e. Facebook) in a landmark case that might (and likely should) change our interpretation of section 230. Please tune in to hear the details of the case and the various ways it could change the social media landscape. It's fascinating!

Prof. Jeff Jarvis - Rewriting Media's Business Model (Yet Again)

May 24, 2024

Jeff Jarvis is a journalism professor at the City College in New York (CUNY), the author of six books, and the cohost of the successful podcast "This week in Google and AI". Jeff spent many years teaching entrepreneurial journalism - and God knows journalism could use some entrepreneurial spirit, right about now. Please check out Jeff's books, The Gutenberg Parenthesis and Magazine, both from Bloomsbury (discount codes here: gutenbergparenthesis.com).

Donald Robertson - Where Philosophy Meets Psychology

June 22, 2024

Our guest today is Donald Robertson - Donald is a cognitive-behavioral psychotherapist and author of several books, including How to Think Like a Roman Emperor and, more recently, Marcus Aurelius: The Stoic Emperor. He is one of the founders of the Modern Stoicism nonprofit organization and the founder and president of the Plato's Academy Centre in Athens, Greece. He was born in Scotland but now lives in Montreal, Canada. His upcoming book, How to Think Like Socrates, will be released later this year, and can be preordered on Amazon, Barnes and Noble, or anywhere else books are generally sold.

Rick Edmonds - Analyzing the Financial Decline of Legacy Media

July 8, 2024

Rick Edmonds is the media business analyst for the Poynter Institute, a school and study center for working journalists. He has been doing research and writing for 25 years on the financial decline of legacy media, newspapers particularly, and the rise of new media alternatives. His reporting and commentary appear regularly on the Poynter Online site. He has spoken to conference groups in the U.S.A. and in Paris, Norway, Madrid, Vienna and Chile.

Jonathan Green - How To Make ChatGPT and Other Tools Useful (Right Now)

July 5, 2024

Welcome to the Otherweb. Our guest today is Jonathan Green - a bestselling author of hundreds of books, a celebrity ghostwriter, and an expert in using artificial intelligence tools to their utmost capacity. This is the best conversation I've had on the practical implications of ChatGPT and how regular people can augment their own capabilities by using these tools as a shortcut.

1h 4m

📌 Trump’s Picks, Rules ‘Rushed,’ More

Angela Palmer

•

TOP STORY

TOP STORY

Trump picks campaigners for key positions

WORLD

WORLD

Approval of ‘climate credit’ rules was rushed

POLITICS

POLITICS

Ruben Gallego wins Arizona US Senate race

All Stories

Summary

Article Metadata

Summit Therapeutics Stock Surges

This is a news story, published by Yahoo Finance, that relates primarily to Summit news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Summit Therapeutics

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest new drug Ivonescimab news, lung cancer antibody Ivonescimab news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

L1 lung cancer drugs

The Motley Fool

The Motley Fool

•

Shares of Summit Therapeutics rocketed 123.4% this week. Here's why

The Motley Fool

Summary

Nutrition label

66% Informative

Summit Therapeutics' new drug Ivonescimab bested Keytruda in a phase 3 clinical trial.

Wall Street analysts hiked their price targets on Summit 's stock.

Management took advantage of Wall Street's enthusiasm to raise $235 million in an equity raise announced Thursday .

It's very difficult to know whether Summit is a buy or not at this point.

VR Score

53

Informative language

50

Neutral language

25

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

8

https://www.fool.com/author/16731/https://www.fool.com/terms/b/blockbuster-drug/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83 https://www.fool.com/investing/2024/09/13/why-summit-therapeutics-skyrocketed-123-this-week/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83 https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=71be5919-b0f9-4bfe-8480-fd5f9dae6696&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D10993%26source%3Disaeditxt0010951%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_yahoo%26ftm_pit%3D16425&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83 https://www.fool.com/legal/fool-disclosure-policy/https://www.fool.com/investing/2024/09/09/why-summit-therapeutics-rocketed-over-60-today/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83 https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=71be5919-b0f9-4bfe-8480-fd5f9dae6696&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D10993%26source%3Disaeditxt0010951%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D16425%26ftm_veh%3Darticle_pitch_feed_yahoo%26company%3DSummit%2520Therapeutics&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83 http://marketintelligence.spglobal.com/

Source diversity

3

www.fool.com api.fool.com marketintelligence.spglobal.com

Affiliate links

no affiliate links

Read full article